drugset / Trial / NCT00058123
Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma
Phase 2
Completed
55 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Biological therapies such as poly-ICLC use different ways to stimulate the immune system and stop tumor cells from growing. PURPOSE: This phase II trial is studying how poly-ICLC works in treating patients with recurrent, progressive, or relapsed anaplastic glioma.
Timeline
- Start
- 2003-03-07
- Primary completion
- 2007-10-06
- Completion
- 2009-01-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hiltonol | Other / unclassified | 20 ug/kg | Intramuscular |